Phaseline

Companies › Ranok Therapeutics (Hangzhou)

Ranok Therapeutics (Hangzhou): clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RNK08954
KRAS G12D inhibitor
KRASPhase 2KRAS G12D MutationsNov 2026
RNK08954-01
KRAS G12D inhibitor
KRASPhase 1KRAS G12D MutationDec 2026
RNK05047
Chaperone-mediated protein degrader
–Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05487170RNK05047Phase 1Advanced Solid TumorOncologyJun 2025
NCT07303465RNK08954Phase 2KRAS G12D MutationsOncologyNov 2026
NCT06667544RNK08954-01Phase 1KRAS G12D MutationOtherDec 2026

Targets

KRAS (2)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Companies built like this

Kumquat Biosciences Genfleet Therapeutics (Shanghai) Jacobio Pharmaceuticals Abbisko Therapeutics HUYABIO International

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.